Publications by authors named "Eva Corey"

Claim this Profile
T
Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer.
Yongtao Li, Zhicheng Zhou, Yiqun Zhang, Deyong Jia, Ding Wang, Eva Corey

Oncogene· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction.
Hee-Young Jeon, Sudeep Khadka, Majid Pornour, Hyunju Ryu, Hegang Chen, Eva Corey

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDC7 is a targetable regulator of advanced prostate cancer.
Alifiani B Hartono, HyeonJi Hwang, Sidharth Paparaju, Shiqin Liu, James D Brooks, Eva Corey

Sci Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target.
Xiong Zhang, Yatian Yang, Hongye Zou, Demin Cai, Eva Corey

Proc Natl Acad Sci U S A· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.
Mitchell G Lawrence, Shivakumar Keerthikumar, Scott L Townley, Ashlee K Clark, Georgia B Cuffe, Eva Corey

Eur Urol Focus· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer.
Ujjwal R Dahiya, Sangeeta Kumari, Nidhi Singh, Chitra Rawat, Eduardo Cortes, Eva Corey

Cell Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer.
Maria Malvina Tsamouri, Stephen J Libertini, Salma Siddiqui, Maitreyee K Jathal, Blythe P Durbin-Johnson, Eva Corey

Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer.
Martine P Roudier, Roman Gulati, Erolcan Sayar, Radhika A Patel, Micah Tratt, Eva Corey

J Clin Invest· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer.
Shipra Shukla, Dan Li, Woo Hyun Cho, Dana M Schoeps, Holly M Nguyen, Eva Corey

J Clin Invest· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer.
Lisanne Mout, Thaidy Moreno-Rodriguez, Giacomo Grillo, Ankita Nand, Tina Keshavarzian, Eva Corey

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.
Tesa M Severson, Emma Minnee, Yanyun Zhu, Karianne Schuurman, Holly M Nguyen, Eva Corey

Cell Rep Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROX1 is an early driver of lineage plasticity in prostate cancer.
Zhi Duan, Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, Dhruv Khokhani, Eva Corey

J Clin Invest· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
Nicole A Traphagen, Esmé Wheeler, Rong Li, Feng Lu, Buraq Ahmed, Eva Corey

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated proteomic portrait of prostate cancer progression.
Jichang Zhang, Keith D Rivera, Daniela Bossi, Federico Gianfanti, Simone Nicastri, Eva Corey

Cell Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer.
Anbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, Eva Rodansky, Xiao-Ming Wang, Eva Corey

Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Eva Corey

Oncogene· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Andreas Varkaris, Keshan Wang, Mannan Nouri, Nina Kozlova, Daniel R Schmidt, Eva Corey

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.
Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Eva Corey

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.
Xiong Zhang, Yatian Yang, Hongye Zou, Yang Yang, Xingling Zheng, Eva Corey

Acta Pharm Sin B· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
Jing Wei, Jing Wang, Wen Guan, Jingjing Li, Tianjie Pu, Eva Corey

EMBO Mol Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
Samuel P Pitzen, Amber N Rudenick, Yinjie Qiu, Weijie Zhang, Sarah A Munro, Eva Corey

Proc Natl Acad Sci U S A· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
Larysa Poluben, Mannan Nouri, Jiaqian Liang, Shaoyong Chen, Andreas Varkaris, Eva Corey

Cell Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
confers resistance to antiandrogens: mechanism and therapeutic implications.
Arunachalam Sekar, Rishita Chatterjee, Boobash Raj Selvadurai, Lipika R Pal, Aakanksha Verma, Eva Corey

bioRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit.
Ilya S Senatorov, Joel Bowman, Keith H Jansson, Aian Neil Alilin, Brian J Capaldo, Eva Corey

Cell Rep Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule disruption of androgen receptor-dependent chromatin clusters.
Sarah E Kohrt, Emily J Novak, Subhashish Tapadar, Bocheng Wu, Jonathan Strope, Eva Corey

Proc Natl Acad Sci U S A· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis